Risk-based approach to setting sterile filtration microbial bioburden limits - Focus on biotech-derived products
Karoline Bechtold-Peters1, Stephen Chang2, Andrew C Lennard3
1Novartis Pharma AG, Basel, Switzerland.
Abstract:
Holistic concepts should be applied that reduce risks prior to final bioburden testing and sterile filtration, based on enhanced process and product attribute understanding, which could be key to successful bioburden risk management. Key findings of this paper include.
More Related Videos
06:36Establishing the Minimal Bactericidal Concentration of an Antimicrobial Agent for Planktonic Cells MBC-P and Biofilm Cells MBC-B
Published on: January 2, 2014
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Products: Biologics, Biosimilars and Interchangeables
Methods for Controlling Microbial Growth
Physical Methods for Controlling Microbial Growth: Radiation and Filtration
Scale-Up Processes
Upstream Processing
